FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1636682021> ?p ?o ?g. }

• W1636682021 abstract "Trial registration: ISRCTN: 68689512 MREC No: 13/LO/0636 UKCRN ID: 14979 INTRODUCTION: One-third of breast cancers diagnosed are non-palpable. These breast cancers require localization-guided surgery and axillary staging using sentinel lymph node biopsy (SLNB). We present our experience of the first 20 patients undergoing a novel technique of magnetic-guided lesion localization and concurrent SLNB, avoiding the need for wire-guided localization and radioisotopes. MATERIALS AND METHODS: Co-localization of the primary tumour and sentinel lymph nodes (SLNs) using a novel magnetic technique was initially undertaken on a protocol-driven predefined minimum of 10 patients with palpable breast cancers to assess the feasibility of the magnetic tracer to safely localize at the point of injection and concurrently drain to the lymphatics. In order to confirm proof of principle, the subsequent 20 patients with non-palpable breast cancers were analysed. An ultrasound-guided intra-tumoral injection of magnetic tracer was performed (0.5 mL Sienna+, Endomagnetics Ltd, UK). Once successful lesion localization was confirmed (peak magnetometer counts retained at the site of injection), the technique was undertaken in patients with non-palpable breast cancers awaiting wide local excision and SLNB. All patients underwent SLNB with the magnetic and combined technique (radioisotope and Patent Blue Dye). RESULTS: A total of 33 patients were recruited and 1 patient excluded due to breach of the trial protocol. This left a remainder of 32 patients for consideration, of which 12 patients (1 bilateral) possessed palpable breast cancer and 20 patients non-palpable breast cancer. Peak magnetometer counts were retained at the site of injection in all palpable (n=13) and non-palpable (n=20) breast cancers. Re-excisions (second operations) for involved margins were performed in 2 patients with non-palpable breast cancers (10%). The mean volume of excised specimens was 49 cm3 (SD 30.6). The SLN identification rate for the magnetic technique alone was 84% (28/33) overall and 85% (17/20) for non-palpable lesions. For the combined technique (radioisotope and blue dye) the SLN identification rate was 97% (32/33) overall and 100% (20/20) for non-palpable lesions. When the magnetic technique is combined with blue dye, the SLN identification rate overall was 97% (32/33) and for non-palpable breast cancers was 95% (19/20). The mean number of sentinel nodes excised was 1.75 versus 2.05 for the magnetic and combined techniques respectively. CONCLUSION: Magnetic lesion localization and concurrent SLNB is a feasible technique. Further optimisation and validation of this technique, in a larger trial, is required. Citation Format: Muneer Ahmed, Ashutosh Kothari, Hisham Hamed, Sumit Goyal, Tibor Kovacs, Anand David Purushotham, Bauke Anninga, Phillippa Young, Julie Scudder, Sarah McWililliams, Sarah Pinder, Quentin Pankhurst, Ian Monnypenny, Michael Douek. Magnetic sentinel node and occult lesion localization in breast cancer: Initial results of the MagSNOLL trial [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-16-09." @default.
• W1636682021 created "2016-06-24" @default.
• W1636682021 creator A5008441610 @default.
• W1636682021 creator A5010137065 @default.
• W1636682021 creator A5013185687 @default.
• W1636682021 creator A5019886247 @default.
• W1636682021 creator A5027894099 @default.
• W1636682021 creator A5032639982 @default.
• W1636682021 creator A5036586660 @default.
• W1636682021 creator A5048402253 @default.
• W1636682021 creator A5048777193 @default.
• W1636682021 creator A5055005629 @default.
• W1636682021 creator A5056747437 @default.
• W1636682021 creator A5059868944 @default.
• W1636682021 creator A5064634344 @default.
• W1636682021 creator A5067302244 @default.
• W1636682021 date "2015-04-30" @default.
• W1636682021 modified "2023-09-27" @default.
• W1636682021 title "Abstract P1-16-09: Magnetic sentinel node and occult lesion localization in breast cancer: Initial results of the MagSNOLL trial" @default.
• W1636682021 doi "https://doi.org/10.1158/1538-7445.sabcs14-p1-16-09" @default.
• W1636682021 hasPublicationYear "2015" @default.
• W1636682021 type Work @default.
• W1636682021 sameAs 1636682021 @default.
• W1636682021 citedByCount "0" @default.
• W1636682021 crossrefType "proceedings-article" @default.
• W1636682021 hasAuthorship W1636682021A5008441610 @default.
• W1636682021 hasAuthorship W1636682021A5010137065 @default.
• W1636682021 hasAuthorship W1636682021A5013185687 @default.
• W1636682021 hasAuthorship W1636682021A5019886247 @default.
• W1636682021 hasAuthorship W1636682021A5027894099 @default.
• W1636682021 hasAuthorship W1636682021A5032639982 @default.
• W1636682021 hasAuthorship W1636682021A5036586660 @default.
• W1636682021 hasAuthorship W1636682021A5048402253 @default.
• W1636682021 hasAuthorship W1636682021A5048777193 @default.
• W1636682021 hasAuthorship W1636682021A5055005629 @default.
• W1636682021 hasAuthorship W1636682021A5056747437 @default.
• W1636682021 hasAuthorship W1636682021A5059868944 @default.
• W1636682021 hasAuthorship W1636682021A5064634344 @default.
• W1636682021 hasAuthorship W1636682021A5067302244 @default.
• W1636682021 hasConcept C121608353 @default.
• W1636682021 hasConcept C126322002 @default.
• W1636682021 hasConcept C126838900 @default.
• W1636682021 hasConcept C141071460 @default.
• W1636682021 hasConcept C142724271 @default.
• W1636682021 hasConcept C179671157 @default.
• W1636682021 hasConcept C204787440 @default.
• W1636682021 hasConcept C2775934546 @default.
• W1636682021 hasConcept C2777757722 @default.
• W1636682021 hasConcept C2780212769 @default.
• W1636682021 hasConcept C2780472235 @default.
• W1636682021 hasConcept C2780849966 @default.
• W1636682021 hasConcept C2781167935 @default.
• W1636682021 hasConcept C2781467025 @default.
• W1636682021 hasConcept C520017518 @default.
• W1636682021 hasConcept C530470458 @default.
• W1636682021 hasConcept C71924100 @default.
• W1636682021 hasConceptScore W1636682021C121608353 @default.
• W1636682021 hasConceptScore W1636682021C126322002 @default.
• W1636682021 hasConceptScore W1636682021C126838900 @default.
• W1636682021 hasConceptScore W1636682021C141071460 @default.
• W1636682021 hasConceptScore W1636682021C142724271 @default.
• W1636682021 hasConceptScore W1636682021C179671157 @default.
• W1636682021 hasConceptScore W1636682021C204787440 @default.
• W1636682021 hasConceptScore W1636682021C2775934546 @default.
• W1636682021 hasConceptScore W1636682021C2777757722 @default.
• W1636682021 hasConceptScore W1636682021C2780212769 @default.
• W1636682021 hasConceptScore W1636682021C2780472235 @default.
• W1636682021 hasConceptScore W1636682021C2780849966 @default.
• W1636682021 hasConceptScore W1636682021C2781167935 @default.
• W1636682021 hasConceptScore W1636682021C2781467025 @default.
• W1636682021 hasConceptScore W1636682021C520017518 @default.
• W1636682021 hasConceptScore W1636682021C530470458 @default.
• W1636682021 hasConceptScore W1636682021C71924100 @default.
• W1636682021 hasLocation W16366820211 @default.
• W1636682021 hasOpenAccess W1636682021 @default.
• W1636682021 hasPrimaryLocation W16366820211 @default.
• W1636682021 hasRelatedWork W10385055 @default.
• W1636682021 hasRelatedWork W13181339 @default.
• W1636682021 hasRelatedWork W13315140 @default.
• W1636682021 hasRelatedWork W13507352 @default.
• W1636682021 hasRelatedWork W20048081 @default.
• W1636682021 hasRelatedWork W364012 @default.
• W1636682021 hasRelatedWork W432182 @default.
• W1636682021 hasRelatedWork W5226406 @default.
• W1636682021 hasRelatedWork W5578950 @default.
• W1636682021 hasRelatedWork W6339381 @default.
• W1636682021 isParatext "false" @default.
• W1636682021 isRetracted "false" @default.
• W1636682021 magId "1636682021" @default.
• W1636682021 workType "article" @default.